By Josh Beckerman
Adicet Bio shares fell 54% to $2.15 on Tuesday after the company reported data from an ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma.
The company said Monday the safety and efficacy data were positive, and “these data are exciting and beyond what one might expect to see given that patients enrolled in the study were heavily pre-treated.”
However, JPMorgan Chase analyst Brian Cheng said “mixed” updates left “key questions unanswered.”
JMP Securities and Guggenheim lowered their ratings on Tuesday.
Write to Josh Beckerman at [email protected]
Read the full article here
